Stem Cell: Stem Cells – The Hype & Hope – World Analysis 2009-2024

Stem Cells – The Hype & Hope – World Analysis 2009-2024

Publication date: 23/03/2009

Number of Pages: 155

Stem cell technologies – changes to US regulations to give exciting new hopes and potentially vast commercial opportunities – brand new indepth study

Stem cells represent one of the most promising medical breakthroughs of all time, as our new market report explains. Currently, in 2009, the new US administration is lifting some major restrictions on stem cells technologies. This developmental obstacle now removed, all types of stem cells are available for expanding the therapeutic and commercial potentials, as our new report Stem Cells – The Hype & Hope – World Analysis 2009-2024 explains. Based upon the cells that create and renew all tissues potentially, stem cell therapies could revolutionise the treatment of disease, especially through tissue and organ replacement. Stem cells could provide revolutionary treatments for conditions from diabetes to multiple sclerosis, and from myocardial infarction to chronic obstructive pulmonary disease, amongst many others. Stem cell lines could also change the way pharmaceutical companies assess new chemical entities during R&D.

A conservative estimate places the potential market value of stem cells at over $150bn by late next decade. But will stem cell products be ready to meet regulatory hurdles and market requirements? Where is stem cell research heading today? What stem cell therapies are likely to hit the market from 2009 onwards? Where does the highest value lie in the short-term? What are the commercial threats there? This new visiongain report answers these and other crucial questions about this important developing field, one with vast commercial potential.

Comprehensive analysis of the global stem cells sector and market

Stem Cells – The Hype & Hope – World Analysis 2009-2024 examines stem cells technology critically. We used a comprehensive review of information sources, including consultations with relevant experts. This report provides detailed sales forecasts, discussions of pipeline developments and analyses of important contemporary issues, especially relevant commercial drivers and restraints. This report also covers regulations and ethics. Sources used include commercial databases, industry news, published reports, policy documents and economic research. Importantly, visiongain applied rigorous financial forecasting, qualitative analyses and the assessment of unmet needs. The result is a comprehensive market- and industry-centred report with detailed analysis and informed opinion that you will not find elsewhere.

Why you should buy this report:

Key information that you will find in Stem Cells – The Hype & Hope – World Analysis 2009-2024 includes:

• Analyses of the existing market value for stem cells
• Analyses of the potential market value of stem cell therapies, including detailed revenue forecasts from 2009 to 2024
• Forecasts for existing stem cell markets, including private cord blood banks and Osiris Therapeutics and NuVasive's Osteocel
• Discussions of ethical complications and situations that influence the way stem cell medicine is perceived, researched and conducted
• Analyses of key organisations, suppliers and relevant national laws
• Expert opinions from original research interviews with key opinion leaders in stem cells research and technology
• Informed analyses of the strengths and weaknesses of the technologies from 2009 onwards
• Balanced assessments of commercial drivers and restraints in the stem cells field.
• Visiongain believes that stem cell technologies are progressing rapidly. We predict that more products will enter the market over the coming 5 years, changing the commercial landscape for stem cells.

You can order this report today

Nobody with an interest in the stem cells field can afford to overlook this new market study from visiongain. The market environment in many countries will change, especially after favourable developments in the US in early 2009. Visiongain predicts that revenues for stem cell technologies will increase greatly from 2009 to 2024, with important events shaping trends. Will stem cells revolutionise medicine in the foreseeable future? What are the main obstacles to overcome there? What revenues can be achieved? This report covers those vital questions and many more. Do you want to know more about this important market? You can stay ahead in this exciting field by ordering this report today.

Pricing

Individual license - this entitles one single user to access the report, not suitable for library storage. Available for only

GBP £1,499

Departmental license - this entitles up to 5 individual users in your department to access the report. Available for only GBP £2,999

Site license - allows use of report by an unlimited number of people within the same enterprise location. Available for only GBP £4,999

Global Site license allows use of report by an unlimited number of people within the same enterprise worldwide Available for only

GBP £6,999

Special discounts are available for non profit organisations and academics, please contact me for details.

Ordering

Ordering is simple! All you need to do to order this report is contact Arpan and I will guide you through the process.

You can either call me on TEL: +44 (0)207 549 9939 or email mailto:arpan.desai@vg-sales.com

Alternatively, you can find all the details you need on how to order at the end of this email.

Please feel free to contact me should you have any questions, or wish to purchase a copy, I look forward to hearing from you.

King Regards,

Arpan Desai

Table of Contents

1 Executive Summary
1.1 The Focus of This Report: "Stem Cells Therapy" versus "Regenerative Medicine"
1.2 Crucial Aspects of the Stem Cell Market
1.2.1 Summary Points
1.2.2 Potential Sales Values
1.3 Aims, Scope and Format of This Report
1.3.1 The Speculative Aspects of Assessing the Stem Cell Field
1.3.2 Chapter Outline
1.4 Research Methods

2 Stem Cells: Types and Sources
2.1 Defining Characteristics
2.1.1 Multipotency vs. Pluripotency
2.1.2 Germ Layers and Multipotent Cells
2.2 Embryonic Stem Cells
2.2.1 Abortion Debates, IVF, and Embryonic Stem Cells
2.2.2 Harvesting Human Eggs
2.3 Cybrids: Controversial Animal-Human Hybrids
2.3.1 "Disease in a Dish" Models Using Cybrids
2.3.2 Cybrids and Therapeutic Cloning
2.3.3 Animal or Human?
2.4 Adult Stem Cells
2.4.1 Tissue / Body Part Sources of Adult Stem Cells
2.5 Cord Blood: The "Natural" Source of Embryonic Stem Cells
2.5.1 "Cord-Blood-Derived Embryonic-Like Stem Cells" (CBE)
2.5.2 CBEs: Ethical and Available
2.5.3 Cord Blood Proven to Cure
2.5.4 The Odds of Needing a Blood Stem Cell Transplant
2.5.5 Cord Blood: Private Hope or Public Salvation?
2.5.5.1 Tissue Matching Can be Less Precise with Cord Blood
2.5.5.2 Extra-Familial Tissue Matching
2.5.5.3 Private Cord Blood Banking: Biological Insurance
2.5.5.3.1 Regional Rules on Private Cord Blood Banking
2.5.5.3.2 US Oversight of Cord Blood Stem Cells
2.6 Commercial Potential of Cord Blood Banks: Market Forecast
2.6.1 86% of Banks Established post-2000
2.6.2 Banks' Added Value
2.7 Do Stem Cells Cause Cancer?
2.7.1 Cancer Metastasisation Caused by Rogue Stem Cells?
2.7.2 Potency Re-programming Requires Insertion of Cancerous Gene
2.7.3 Will Stem Cell Treatments Cause Cancer?

3 Established Stem Cell Treatments
3.1 Bone Marrow Transplants: 40+ Years of Success
3.2 Peripheral Blood Stem Cells: Gaining Ground
3.3 Cord Blood Stem Cells
3.4 Graft-Versus-Tumour Effect: Donated Cells Kill Host's Cancer Cells
3.4.1 Allogenic Transplants are Better for Killing Cancer
3.5 Graft-Versus-Host Disease: When Host and Transplant Do Not Mesh
3.5.1 Prochymal: Treatment for GvHD
3.6 Host-Versus-Graft: When Stem Cells are Rejected
3.7 "Saviour-Siblings": Stem Cells from a Sibling, Created or Chosen to be a Saviour
3.7.1 UK Cases and Rules on Saviour Siblings
3.7.2 Regardless of the Ethics, Saviour Sibling Stem Cells Work

4 Emerging Stem Cell Treatments
4.1 Prochymal - Poised to be the First Revolutionary Stem Cell Treatment
4.1.1 Market Value of Prochymal Indications
4.1.2 Crohn's Disease
4.1.3 Chronic Obstructive Pulmonary Disease
4.1.4 Diabetes and Prochymal
4.1.5 Cardiac Indications
4.1.6 Graft-Versus-Host Disease
4.1.7 Prochymal and Acute Radiation Syndrome
4.1.7.1 Proof-of-Concept for Prochymal for ARS
4.2 Osteocel Market Forecast: Osiris's First Marketed Product, Now Sold by NuVasive
4.2.1 Osteocel: The Only Marketed Product with Viable Stem Cells
4.2.2 Osteocel XC
4.3 Other Wound Healing / Surgical Healing
4.4 Heart and Artery Repair
4.5 Autoimmune Diseases
4.5.1 Crohn's Disease
4.5.2 Diabetes Types 1 and 2
4.5.3 Multiple Sclerosis
4.6 Reducing Rejection: Addressing Graft-Versus-Host Disease
4.7 Paralysis Treatments: Geron's GRNOPC1. (The First Embryonic Stem Cell Clinical Trial)
4.7.1 How Much GRNOPC1 Can Geron Make?
4.8 Therapeutic Cloning / Somatic Cell Nuclear Transfer
4.8.1 Organ Transplants: Can Therapeutic Cloning Make Them Obsolete?
4.8.2 Growing Organs
4.8.3 Somatic Cell Nuclear Transfer for Disease Models

5 Leading Stem Cell Therapy Companies
5.1 Osiris: First to Market with Stem Cells
5.1.1 Prochymal and 2008
5.1.2 Osiris and NuVasive
5.1.3 Osteocel Sales Forecast
5.1.4 Osiris and Genzyme Marketing Agreement
5.1.5 Osiris and Boston Scientific: Partnership Ended 2008
5.2 Genzyme
5.3 Geron: First Embryonic Stem Cell Trial
5.4 Novocell: Looking to Follow Geron in Embryonic Stem Cell Trials
5.4.1 Johnson & Johnson and Novocell
5.4.2 Pfizer and Novocell
5.5 Pfizer and Induced Pluripotent Stem Cells (iPS)
5.6 Novartis: The Genomics Institute of the Novartis Research Foundation (GNF)
5.7 MediStem, Inc. (MediStem Laboratories, Inc.)
5.8 Regenetech
5.8.1 Biogenea-CellGenea
5.9 Neuralstem, Inc.
5.10 Advanced Cell Technology (ACT)
5.10.1 ACT and Transition Holdings, Inc.
5.10.2 ACT and CHA Biotech Co., Ltd.
5.10.3 ACT Acquired Mytogen, Inc.
5.11 Garnet BioTherapeutics / Neuronyx
5.12 Pluristem Therapeutics, Inc.
5.13 BrainStorm Cell Therapeutics
5.14 Cellerix: Ontari has EMA Orphan Drug Status
5.15 ReNeuron
5.16 CellCure Neurosciences, Ltd.
5.17 Athersys
5.18 Royan Institute (Tehran)
5.19 Reliance Life Sciences, India
5.20 Cytori Therapeutics

6 Major Stem Cell Suppliers
6.1 StemCell Technologies
6.1.1 Geron and StemCell Technologies
6.2 ES Cell International, Singapore: Aiming for the First Marketed Product Including Embryonic Stem Cells
6.3 Stemride International Limited (SIL) and Reproductive Genetics Institute, Chicago: Normal and Abnormal Cell Lines
6.4 Merck / Calibochem
6.4.1 Stem Cell Sciences and Merck
6.5 Cellular Dynamics International (CDI)
6.5.1 Roche and Cellular Dynamics: Pioneering Toxicity Assays
6.6 HyClone / Thermo Fisher Scientific
6.7 Stemgent
6.8 Stem Cell Innovations (SCI)
6.9 Axiogenesis (Germany)
6.9.1 Roche and Axiogenesis
6.10 StemLifeLine: Embryonic Stem Cells Without Embryo Destruction?

7 Overview of Regional Embryonic Stem Cell Regulations and Funding Bodies
7.1 Pan-Europe: Roche, GlaxoSmithKline and AstraZeneca
7.2 United States
7.2.1 California Stem Cell Research and Cures Initiative (Proposition 71) and The California Institute for Regenerative Medicines
7.2.1.1 Stanford University Received $75 Million for Stem Cell Research
7.2.1.2 UC Irvine Received $27 Million for Stem Cell Research Center
7.3 United Kingdom
7.3.1 The London Regenerative Medicine Network (LRMN)
7.4 Sweden
7.5 Switzerland
7.6 Belgium
7.7 France: Reassessing Embryonic Research in 2009
7.8 Less-Permissive European Countries for Stem Cells
7.8.1 Germany
7.8.2 Norway
7.8.3 Italy
7.9 Canada
7.10 Russia
7.11 Israel: At the Forefront of Research; Reproductive Cloning Ban Up for Reassessment in 2009
7.12 Gulf Countries: Funding Biotechnology, Funding Stem Cell Research
7.13 Singapore: Advanced and Prominent in Stem Cells
7.14 China: Open to the Potential of Stem Cell Technologies
7.15 India: First Stem Cells Facility Due to Open in 2009
7.16 Australia and the Australian Stem Cell Centre
7.17 Japan
7.18 South Korea
7.19 South Africa

8 Visiongain Interviews with Stem Cell Experts
8.1 Dr. Johan Luthman, PhD., Global Head of Exploratory Medicine (Neurology, Autoimmune & Inflammatory Diseases), Merck Serono (a division of Merck KGaA)
8.1.1 On the Difficulties of Translational Medicine
8.1.2 On the Differences Between Technology and Media Perceptions
8.1.3 On Confusion in the Media
8.1.4 On Stem Cells and Neurologic Disorders
8.1.4.1 On Which Neurological Disorders will be Treated First
8.1.4.2 On Multiple Sclerosis
8.1.5 On Why Stem Cell Results Take a Long Time
8.1.6 On When Stem Cell Therapies Will Reach the Market
8.1.7 On the Distinction between Regenerative Medicine and Stem Cell Therapies
8.2 Dr Stephen Minger, Senior Lecturer and Director of King's College London's Stem Cell Biology Laboratory (Wolfson Centre for Age-Related Diseases)
8.2.1 On Whether Adult or Embryonic Stem Cells Should Receive More Funding/Support
8.2.2 On Cord Blood and Embryonic Stem Cells
8.2.3 On the Need for More Immunological Assays
8.2.4 On How Long Until There are Human Stem Cell Therapies
8.2.5 On Cord Blood as a Source of Stem Cells
8.2.6 On Private Cord Blood Banking
8.2.7 On Therapeutic Cloning
8.2.7.1 On Therapeutic Cloning and Tissue Type Cell Lines
8.2.8 On the Promising and Unusual Immunological Properties of Embryonic Stem Cells
8.2.9 On Mesenchymal Stem Cells and Inflammation
8.2.10 On the Suggestive Use of Foreskin Fibroblasts
8.3 Gregory Bonfiglio, Proteus Venture Partners
8.3.1 On the Terms "Stem Cell Therapy" and "Regenerative Medicine"
8.3.2 On "Near Term" Applications
8.3.3 On the Value-Creation Curve for Venture Capital in Stem Cells
8.3.4 On There Being No Known Limits for Stem Cell Possibilities
8.3.5 On Stem Cells in 25 Years
8.3.6 On Funding as a Primary Limitation
8.3.7 On Stem Cells in Multiple Sclerosis and Diabetes Type 1
8.3.8 On Cord Blood
8.3.9 On Extracellular Matrixes
8.3.10 On Disease-Specific Cell Lines
8.3.11 On Adult vs. Embryonic Stem Cells
8.3.12 On Where There is Capital for Stem Cell and Regenerative Medicine Research
8.4 Josephine Quintavalle, Founder of Comment on Reproductive Ethics (CORE)
8.4.1 On Embryonic Stem Cells and Dehumanisation
8.4.2 On HFEA Regulation for Embryo Destruction
8.4.3 On Economics and Scientific Effectiveness
8.4.4 On Cord Blood
8.4.5 On Adult Stem Cell Therapies and the Economics of Therapy
8.4.6 On Public, Private and Private/Public Cord Blood Banks
8.4.7 On International Studies and International Communication

9 Market Value Potentials and Projections
9.1 Visiongain's Stem Cells Market Projection
9.1.1 Complexities of Analysis
9.1.2 Bases for Visiongain's Market Projection
9.2 Forecast by Market Subdivision
9.2.1 Laboratory Supplies
9.2.2 Bone Marrow Transplants
9.2.3 Organs and Tissues

10 SWOT Analysis
10.1 Strengths and Weaknesses
10.1.1 Strength in Numbers
10.1.2 Weakness in Fragmentation
10.1.3 Weakness in Funding Uncertainties
10.2 Opportunities and Threats
10.2.1 Opportunities Abound
10.2.2 The Constant Threat of Politics

11 Conclusions
11.1 The Hope
11.2 The Hype
11.3 The Short-Term Future
11.4 The Long-Term Future

Appendix: Religious Perspectives on (Embryonic) Stem Cells
1 Catholicism
2 Protestantism
3 Judaism
4 Islam
5 Hinduism

List of Tables
Table 2.1 Types of Cellular Potency and Sources of Cells
Table 2.2 Germ Layers and Associated Cells/Organs
Table 2.3 Adult Stem Cell Sources
Table 2.4 Private / Family Cord Blood Banks Sales Forecast, 2009-2024
Table 4.1 Market Value of Selected Prochymal Future Indications, Based Upon Sales Through Q3 2008
Table 4.2 Osteocel Sales Forecast, 2009-2024 (including Osteocel XC)
Table 4.3 Clinical Trials of Stem Cell Studies for Surgical or Injury Healing, Phases I-III, 2009
Table 4.4 Stem Cell Heart Repair Clinical Trials, Phases III-IV, 2009
Table 4.5 Clinical Trials for Autoimmune Diseases (non-Prochymal), Phases I-III, 2009
Table 4.6 Clinical Trials for Graft-Versus-Host Disease, Phase II-III, 2009
Table 4.7 Countries' Donor Systems (Opt-in vs. Opt-out), 2009
Table 5.1 Osteocel Sales Forecast, 2009-2024
Table 9.1 Stem Cells Sales Forecasts, Total Market and by Sub-Market, 2009-2024
Table 10.1 Strengths and Weaknesses in the Stem Cells Market, 2009-2024
Table 10.2 Opportunities and Threats in the Stem Cells Market, 2009-2024

List of Figures
Figure 2.1 Private / Family Cord Blood Banks Sales Forecast, 2009-2024
Figure 4.1 Market Value of Selected Prochymal Future Indications, Based Upon Sales Through Q3 2008
Figure 4.2 Osteocel Sales Forecast, 2009-2024
Figure 5.1 Osteocel Sales Forecast, 2009-2024
Figure 9.1 Stem Cells Total Market Sales Forecast, 2009-2024
Figure 9.2 Stem Cells Sales Forecasts by Sub-Market, 2009-2024

Companies Listed

Advanced Cell Technology
Alliance Technology Ventures
American Spinal Injury Association (ASIA)
Anthony Nolan Trust
Assisted Human Reproductions Agency, Canada
AstraZeneca
Athersys
Australian Stem Cell Centre
Axiogenesis AG
Barts & The London NHS Trust
Bayer Schering Pharma
Biogenea-CellGenea
Blutspendedienst Baden-Württemberg - Hessen
Boston Scientific Corp.
BrainStorm Cell Therapeutics
Calibochem
California Institute for Regenerative Medicines (CIRM)
Cambridge University Hospitals
Canadian Institute of Health
Canadian Institutes of Health Research (CIHR)
CellCure Neurosciences, Ltd.
Cellerix
Cellular Dynamics
Cellular Engineering Technologies
Centre for Cellular and Molecular Biology, India
CHA Biotech Co., Ltd, Korea
Children's Hospital & Research Center, Oakland, California
Christian Medical College, Vellore, India
Clinical Research Facility for Stem Cells and Regenerative Medicine, India
Comment on Reproductive Ethics (CORE)
Cord Blood Registry, US
Cordon Vital (CBR), Mexico
Cryo-Cell International
Cytori Therapeutics
Department of Defense (US)
Deutsches Herzzentrum Muenchen
Duke University
Eli Lilly and Company
Else Kröner Fresenius Foundation
ES Cell International, Singapore
European Group for Blood and Marrow Transplantation
European Medicines Agency (EMA)
European Union Group on Ethics (EGE)
Financiadora de Estudos e Projetos (FINEP)
Food and Drug Administration (FDA)
Franziskus-Krankenhaus
Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (FAPERGS)
Garnet BioTherapeutics
Genzyme
German Heart Institute
Geron
Guidant Corporation
Hadassah Medical Organization
Haematology Service, University Hospital of Salamanca
Harvard Biosciences, Inc.
Harvard Stem Cell Institute
Health Resources and Services Administration
Human Fertilisation and Embryology Authority (HFEA)
Imperial College London
Institute for Medical Sciences, Nizam
Instituto de Cardiologia do Rio Grande do Sul
iPS Cells
Israeli Health Ministry
Johann Wolfgang Goethe University Hospitals
Johns Hopkins University
Johnson & Johnson Development Corporation
King's College London
Kingston University, Surrey, UK
Korea Stem Cell Bank Co., Ltd. (KSCB)
Krankenhaus der Barmherzigen Brüder Trier
Leids University Medical Centre
LifeCell India
London Development Agency
London Regenerative Medicine Network (LRMN)
M.D. Anderson Cancer Center
Medical Research Council
MediStem, Inc.
Memorial Sloan-Kettering Cancer Center
Merck KGaA
Merck Serono
Miltenyi Biotec
Ministry of Health, Brazil
Ministry of Health, Iran
Ministry of Science and Higher Education, Poland
Mytogen, Inc.
National Cancer Institute (NCI)
National Marrow Donor Program
NephrosNeuralstem, Inc.
Neuronyx
NHS Foundation Trust
Northwestern University
Northwestern University Feinberg School of Medicine, Chicago
Novartis
Novocell
NuVasive, Inc.
OSI Pharmaceuticals
Osiris Therapeutics
Parent's Guide to Cord Blood Foundation
Pfizer
Pluristem Therapeutics, Inc.
Postgraduate Institute of Medical Education and Research, India
Primogenix
ProLife Alliance
Proteus Venture Partners
Queen Mary University of London
Radius Medical, LLC
Regenetech
Reliance Life Sciences
ReNeuron
Reproductive Genetics Institute, Chicago
Roche
Royan Institute, Tehran
Safeguard Scientifics, Inc.
Schulz Foundation
SCP Vitalife Partners
Silesian School of Medicine
Singapore Stem Cell Consortium
SRH Klinikum Karlsbad-Langensteinbach
Stem Cell & Regenerative Medicine International
Stem Cell Authority, Ltd.
Stem Cell Biology and Regenerative Medicines Institute, Stanford University
Stem Cell Innovations
Stem Cell Network, Canada
Stem Cell Products Inc.
Stem Cell Research Forum of India (SCRFI)
Stem Cell Sciences
Stem Cells for Safer Medicines (SC4SM)
StemCell Technologies
Stemgent
StemLifeLine
Stemride International Limited
Stiftungsklinikum Boppard
Swiss Stem Cells Network
Texas A&M University
The Broad Foundation
The Genomics Institute of the Novartis Research Foundation
Thermo Fisher Scientific (formerly HyClone)
Transition Holdings, Inc., Ireland
UC Irvine
Universidad Autónoma de Madrid
University College London
University Hospital of Liege
University Hospital, Basel, Switzerland
University of Cambridge
University of Louisville
University of Minnesota
University of Ottawa
University of Oulu, Finland
University of Salamanca
University of Southern California
University of Texas Medical Branch, Galveston
University of Washington
US Department of Health and Human Services
ViaCell, Inc.
Washington University School of Medicine
Wilhelm Sander Foundation
World Marrow Donor Association

How to Order

We have two available payment options. You can choose to pay by invoice, or alternatively by credit card, you will be sent the report by email in pdf format within a maximum of 24 hours (transfer time is usually 1-2hrs) once we have received your payment:

Details required:

-Company Name –

-Name of user -

-Email Address of user -

-Users' Job Title-

-Postal Address -

-Contact Telephone Number -

-Fax Number -

-EEC VAT number (if applicable)-

Additional details for Credit Card payments

-Type of card -

-Card number -

-Expiry date -

-Issue number (if applicable) -

-Security number (3 digits, or 4 digits for Amex cards) -

All details may be provided by replying to this email, on phone or sent through fax.

Licences

Single User License: This license allows for use of a report by one person. This person may use the report on any computer, and may print out the report, but may not share the report (or any information contained therein) with any other person or persons. Unless a Departmental License, a Site License or a Global Site License is purchased, a Single User License must be purchased for every person that wishes to use the report within the same enterprise. Customers who infringe these license terms are liable for a Global Site license fee.

Departmental Licenses: This license allows for use of a report by five people within the same enterprise location. Each of these people may use the report on any computer, and may print out the report, but may not share the report (or any information contained therein) with any other person or persons. Customers who infringe these license terms are liable for a Global Site license fee.

Site License: This license allows for use of a report by an unlimited number of people within the same enterprise location. Each of these people may use the report on any computer, and may print out the report, but may not share the report (or any information contained therein) with any person or persons outside of the enterprise location. Customers who infringe these license terms are liable for a Global Site license fee.

Global Site License: This license allows for use of a report by an unlimited number of people within the same enterprise worldwide. Each of these people may use the report on any computer, and may print out the report, but may not share the report (or any information contained therein) with any other person or persons outside of the enterprise.

Unsubscribe:

As a valued contact or customer of Visiongain, you are receiving this email with information that we believe will be relevant to you. If, however, you do not wish to receive future messages, please reply to this message, typing 'unsubscribe' in the subject box of your email.

We support responsible and ethical email marketing practices. Please know that we respect your right to be purged from this marketing campaign.

Please allow 48 hours to remove your email address. Thank you for your cooperation.

Click here to Unsubscribe

Who we are:

Visiongain is an independent business information provider for the Telecoms, Pharmaceutical and Defence industries. We organise conferences, publish reports and newsletters, and provide consultancy services.

Established in 1999, we have built a strong reputation for covering business-critical topics and investigating issues that other information providers will not. We are completely independent, we are not associated with any parent organisation or with the subjects of any of our analysis, and we are not led by PR firms or advertisers.

We look forward to working with you. If you have any questions, please contact us.

Terms and Conditions for management reports

By replying to this e-mail submitting your order for this product you have agreed without limitation or qualification to be bound by and to comply with these Terms and Conditions. You agree that you will not fail to complete any transaction after submitting an order to purchase a product or submit any order to purchase a product where you do not intend to complete the transaction.

Management Reports will only be sent on receipt of payment.

Terms & Conditions for conferences

NB - Due to high demand, we do not 'reserve' or 'hold' places - a request for an invoice to be raised will be treated as an official booking and will be subject to the cancellation policy as outlined below. Cancellations/substitutions and name changes: All bookings carry a 50% liability after the booking has been made, by post fax, email or web. There will be no refunds for cancellations received on or after one month before the start of the conference (e.g. cancellation on or after 20th January for a conference starting on 20th February). If you decide to cancel after this date the full invoice remains payable.

Conference notes, which are available on the day, will be sent to you.

Unfortunately we are not able to transfer places between conferences and executive briefings. However if you are unable to attend the event you may make a substitution/name change at any time as long as we are informed in writing by e-mail, fax or post. Name changes and substitutions must be from the same company and are not transferable between companies or countries.

Indemnity: visiongain Ltd reserve the right to change the conference/executive briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled due to acts of terrorism, war, extreme weather conditions, industrial action, acts of God or any event beyond the control of visiongain Ltd. If such a situation arises we will endeavour to reschedule the event. However, visiongain Ltd cannot be held responsible for any cost, damage or expenses, which may be incurred by the customer as a consequence of the event being postponed or cancelled. We therefore strongly advise all customers to take out insurance to cover the cost of the registration, travel and expenses.

Contact Details:

Tel: +44 (0)207 549 9939

Email: Arpan Desai

Visiongain

Reports and Conferences

You may also be interested in:

Global Biotech Market Analysis and Forecasts, 2008-2023

The biotechnology industry is a major growth area in the global healthcare market, one upon which many companies are placing their hopes. Due to developments in monoclonal antibodies, genomics and proteomics - amongst others - the biotechnology market has experienced great expansion since its emergence during the 1970s.